MAPK3 and neoplasm: Liao et al. (2020) examined the effectiveness of EGCG‐derived Y6 against HCC and concluded that the EGCG derivative Y6 significantly reduced angiogenesis and tumor progression via modulating the MAPK/ERK1/2 and PI3K/AKT/HIF‐1α/VEGF axis.